US patent for rapid bacterial vaginosis test:
This article was originally published in Clinica
Litmus Concepts has received a third US patent covering its rapid test for bacterial vaginosis (BV). The pH and Amines FemExam TestCard, which was approved by the FDA in 1997, produces a qualitative "yes/no" result, providing an objective means of diagnosing the infection. This replaces the subjective "Whiff" test, which requires the healthcare worker to smell for a characteristic amine odour, said the Santa Clara, California-based company. The new patent covers the use of the device to detect BV as a stand-alone product and when used as part of the clinical criteria for diagnosing BV.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.